Extra-Articular Manifestations of Rheumatoid Arthritis
The correct answers are: a) Pleural effusion, d) Rheumatoid vasculitis, and e) Pulmonary fibrosis. These are all well-established extra-articular manifestations of RA, while glomerulonephritis and Libman-Sacks endocarditis are not characteristic of rheumatoid arthritis.
Analysis of Each Option
a) Pleural Effusion - CORRECT ✓
Pleural effusion is a recognized extra-articular manifestation of RA. Pleuropulmonary involvement occurs frequently in RA and can affect all anatomic thoracic compartments 1. Recent case reports document recurrent exudative pleural effusions as a complication of RA, even occurring without active clinical arthritis 2. Pleural disease is among the most common pleuropulmonary manifestations alongside interstitial lung disease, pulmonary arterial hypertension, and rheumatoid lung nodules 1.
b) Glomerulonephritis - INCORRECT ✗
Glomerulonephritis is NOT a typical extra-articular manifestation of RA. Primary renal involvement in RA is rare and usually relates to drug therapy rather than the disease itself 3. When renal disease occurs in RA patients, it is typically secondary to medications (NSAIDs, DMARDs) or amyloidosis, not primary glomerular inflammation from the rheumatoid process.
c) Libman-Sacks Endocarditis - INCORRECT ✗
Libman-Sacks endocarditis is characteristic of systemic lupus erythematosus (SLE), not rheumatoid arthritis. While RA does have cardiac manifestations including pericarditis and increased cardiovascular disease risk (twice the risk of myocardial infarction compared to the general population 3), the sterile verrucous endocarditis known as Libman-Sacks is pathognomonic for SLE.
d) Rheumatoid Vasculitis - CORRECT ✓
Rheumatoid vasculitis is a rare but serious extra-articular manifestation of RA 4. It typically affects small- and medium-sized vessels and is often associated with high disease activity and seropositivity (rheumatoid factor and anti-citrullinated protein antibodies) 4. The 2026 Pan American League guidelines specifically address this complication, conditionally recommending rituximab treatment for rheumatoid vasculitis 4. While it is becoming rarer over time due to better disease activity control 5, it remains a devastating long-term complication when it occurs.
e) Pulmonary Fibrosis - CORRECT ✓
Pulmonary fibrosis (interstitial lung disease) is a well-established extra-articular manifestation of RA. The 2026 Pan American League guidelines dedicate an entire recommendation to RA-associated interstitial lung disease, conditionally recommending treatment with methotrexate, rituximab, abatacept, or targeted synthetic DMARDs 4. For progressive disease, antifibrotic drugs like pirfenidone or nintedanib are conditionally recommended 4. Pulmonary hypertension and ILD are the manifestations with the greatest negative impact on prognosis 1, and respiratory disease is the second major cause of death in RA patients after cardiovascular disease 3.
Clinical Pitfalls to Avoid
- Don't confuse RA with SLE manifestations: Libman-Sacks endocarditis and glomerulonephritis are lupus features, not RA
- Consider infection as a differential: When evaluating pleural effusions in RA patients, infection must be ruled out, especially given immunosuppressive therapy 6
- Screen high-risk patients for ILD: Male gender, smoking, older age, high rheumatoid factor levels, or positive anti-CCP antibodies warrant HRCT chest screening 1
- Recognize that extra-articular manifestations predict worse outcomes: They are associated with increased mortality and occur more commonly in males despite RA being more prevalent in females 7